Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $551000.0.

  • Janux Therapeutics' Other Accumulated Expenses fell 2917.74% to $551000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $551000.0, marking a year-over-year decrease of 2917.74%. This contributed to the annual value of $918000.0 for FY2024, which is 6721.31% up from last year.
  • Per Janux Therapeutics' latest filing, its Other Accumulated Expenses stood at $551000.0 for Q3 2025, which was down 2917.74% from $587000.0 recorded in Q2 2025.
  • Janux Therapeutics' 5-year Other Accumulated Expenses high stood at $1.0 million for Q2 2023, and its period low was $199000.0 during Q2 2021.
  • In the last 5 years, Janux Therapeutics' Other Accumulated Expenses had a median value of $609000.0 in 2022 and averaged $627833.3.
  • In the last 5 years, Janux Therapeutics' Other Accumulated Expenses soared by 19452.45% in 2023 and then tumbled by 2974.56% in 2024.
  • Quarter analysis of 5 years shows Janux Therapeutics' Other Accumulated Expenses stood at $478000.0 in 2021, then soared by 30.33% to $623000.0 in 2022, then fell by 11.88% to $549000.0 in 2023, then soared by 67.21% to $918000.0 in 2024, then tumbled by 39.98% to $551000.0 in 2025.
  • Its last three reported values are $551000.0 in Q3 2025, $587000.0 for Q2 2025, and $925000.0 during Q1 2025.